Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 434Carcinoma, Non-Small-Cell Lung 360Neoplasms 339Prostatic Neoplasms 276Colorectal Neoplasms 264Multiple Myeloma 206Lung Neoplasms 195Neoplasm Metastasis 179Leukemia, Myeloid, Acute 160Ovarian Neoplasms 155Pancreatic Neoplasms 152Squamous Cell Carcinoma of Head and Neck 138Melanoma 126Recurrence 104Head and Neck Neoplasms 99Glioblastoma 99Carcinoma, Renal Cell 98Endometrial Neoplasms 96Carcinoma, Hepatocellular 93Lymphoma, Non-Hodgkin 92Precursor Cell Lymphoblastic Leukemia-Lymphoma 91Lymphoma 91Triple Negative Breast Neoplasms 90Stomach Neoplasms 88Uterine Cervical Neoplasms 85Brain Neoplasms 85Lymphoma, Large B-Cell, Diffuse 80Urinary Bladder Neoplasms 77Glioma 74Leukemia, Lymphocytic, Chronic, B-Cell 73

Interventions

temsirolimus 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Endometrial Adenocarcinoma × 30 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡